Full history for every metric is available with a Kvantra account
Golden Biotechnology Corporation (4132.TWO)
Key financial summary
Financials in TWD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | TWD m | 83 | 89 | 82 | 218 | 63 | 41 | 45 |
| Operating profit | TWD m | -358 | -305 | |||||
| Net profit | TWD m | -285 | -391 | -444 | -272 | -362 | -361 | -315 |
| EPS reported | TWD | -2.39 | -2.04 | |||||
| Operating cashflow per share | TWD | -1.75 | -1.75 | |||||
| Capex per share | TWD | 0.02 | 0.02 | |||||
| FCF per share | TWD | -1.77 | -1.77 | |||||
| Free cash flow | TWD m | -266 | -239 | |||||
| Net debt | TWD m | 102 | 222 | |||||
| Book value equity | TWD m | 306 | 191 | |||||
| Book value per share | TWD | 2.03 | 1.17 | |||||
| Number of shares | m | 150.61 | 162.23 | |||||
| DPS (TTM paid) | TWD | 0.00 | 0.00 |
Financial summary
Financials in TWD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 7.66 | 3.32 | |||||
| P/S LTM | x | 57.24 | 14.18 | |||||
| P/FCF LTM | x | -8.81 | -2.64 | |||||
| EV/EBITDA LTM | x | -8.14 | -3.17 | |||||
| EV/Sales LTM | x | 60.87 | 19.16 | |||||
| Earnings Yield LTM | % | -15.40% | -69.02% | |||||
| FCF Yield | % | -11.35% | -37.81% | |||||
| Quality | ||||||||
| ROE | % | -117.97% | -101.91% | |||||
| ROIC | % | -52.90% | -52.90% | |||||
| Operating margin | % | -874.18% | -874.18% | |||||
| Gross margin | % | -17.14% | -17.14% | |||||
| FCF/Sales | % | -649.87% | -649.87% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -35.49% | -22.46% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.72 | -0.73 | |||||
| Net Debt/EBITDA | x | -0.49 | -0.49 | |||||
| EBIT/Net interest | x | -42.47 | -42.47 | |||||
| Net debt/market cap | % | 4.34% | 35.06% | |||||
| Net debt/Equity | x | 0.33 | 1.16 | |||||
| Gross debt/equity | x | 1.20 | 1.72 | |||||
Company overview
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Golden Biotechnology Corporation (4132.TWO)
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free